What is Kainova Therapeutics?
Kainova Therapeutics is a clinical-stage biopharmaceutical firm focused on pioneering GPCR modulating therapies for immuno-oncology and inflammation. The company's pipeline includes both small molecule and antibody programs designed to fundamentally alter tumor and immune responses, offering new hope for patients with limited treatment options. With operations spanning Canada and Europe, Kainova is strategically positioned to advance its therapeutic candidates through critical clinical milestones.
How much funding has Kainova Therapeutics raised?
Kainova Therapeutics has raised a total of $23.6M across 1 funding round:
Series B
$23.6M
Series B (2026): $23.6M with participation from CTI Life Sciences Fund, Panacea Ventures, Investissement Quebec, Viva BioInnovator, Schroders Capital, adMare BioInnovations, Turenne Capital, Seventure Partners, and 3B Future Health Fund I & II
Key Investors in Kainova Therapeutics
CTI Life Sciences Fund
CTI Life Sciences Fund is a prominent Canadian venture capital firm specializing in early-stage biotech, focusing on catalyzing innovative ideas into scalable companies with a track record of over 30 investments.
Panacea Ventures
Panacea Capital is a global healthcare venture fund dedicated to driving innovation in biotech, with a portfolio of over 30 private companies focused on next-generation immunotherapeutics and regenerative medicine.
Investissement Quebec
Investissement Quebec is a provincial financial institution that supports business growth and economic development in Quebec through various financial solutions, including equity investments.
What's next for Kainova Therapeutics?
The recent major strategic investment signals a pivotal phase for Kainova Therapeutics, likely enabling the acceleration of its clinical development programs and the expansion of its research and development capabilities. This capital infusion is expected to fuel the progression of its immuno-oncology and inflammation therapies, potentially leading to significant advancements in patient care and market penetration. The company's focus on reshaping tumor and immune responses positions it at the forefront of innovative therapeutic strategies.
See full Kainova Therapeutics company page
